Cargando…
Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several cli...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360113/ https://www.ncbi.nlm.nih.gov/pubmed/17375048 http://dx.doi.org/10.1038/sj.bjc.6603690 |
_version_ | 1782152967630094336 |
---|---|
author | Puppa, G Maisonneuve, P Sonzogni, A Masullo, M Chiappa, A Valerio, M Zampino, M G Franceschetti, I Capelli, P Chilosi, M Menestrina, F Viale, G Pelosi, G |
author_facet | Puppa, G Maisonneuve, P Sonzogni, A Masullo, M Chiappa, A Valerio, M Zampino, M G Franceschetti, I Capelli, P Chilosi, M Menestrina, F Viale, G Pelosi, G |
author_sort | Puppa, G |
collection | PubMed |
description | Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several clinicopathologic parameters and survival. Overall, fascin immunoreactivity was detected in 162 (71%) tumours with a prevalence for right-sided tumours (P<0.001). Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases. Patients with fascin-expressing tumours experienced a shorter disease-free and overall survival in comparison with those with negative tumours, and fascin immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. Moreover, patients with the same tumour stages could be stratified in different risk categories for relapse and progression according to fascin expression. Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas. |
format | Text |
id | pubmed-2360113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23601132009-09-10 Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma Puppa, G Maisonneuve, P Sonzogni, A Masullo, M Chiappa, A Valerio, M Zampino, M G Franceschetti, I Capelli, P Chilosi, M Menestrina, F Viale, G Pelosi, G Br J Cancer Molecular Diagnostics Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several clinicopathologic parameters and survival. Overall, fascin immunoreactivity was detected in 162 (71%) tumours with a prevalence for right-sided tumours (P<0.001). Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases. Patients with fascin-expressing tumours experienced a shorter disease-free and overall survival in comparison with those with negative tumours, and fascin immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. Moreover, patients with the same tumour stages could be stratified in different risk categories for relapse and progression according to fascin expression. Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas. Nature Publishing Group 2007-04-10 2007-03-20 /pmc/articles/PMC2360113/ /pubmed/17375048 http://dx.doi.org/10.1038/sj.bjc.6603690 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Puppa, G Maisonneuve, P Sonzogni, A Masullo, M Chiappa, A Valerio, M Zampino, M G Franceschetti, I Capelli, P Chilosi, M Menestrina, F Viale, G Pelosi, G Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma |
title | Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma |
title_full | Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma |
title_fullStr | Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma |
title_full_unstemmed | Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma |
title_short | Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma |
title_sort | independent prognostic value of fascin immunoreactivity in stage iii–iv colonic adenocarcinoma |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360113/ https://www.ncbi.nlm.nih.gov/pubmed/17375048 http://dx.doi.org/10.1038/sj.bjc.6603690 |
work_keys_str_mv | AT puppag independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT maisonneuvep independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT sonzognia independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT masullom independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT chiappaa independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT valeriom independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT zampinomg independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT franceschettii independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT capellip independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT chilosim independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT menestrinaf independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT vialeg independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma AT pelosig independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma |